Evidence map›Paper›PMID 40801926›Full record

ReviewVirchows Archiv : an international journal of pathology2025

Atypical lymphoid proliferations associated with therapeutic intervention: a report of the 2024 EA4HP/SH lymphoma workshop.

Ioannis Anagnostopoulos, Tanja Lakic, Olga Balague, Michiel Van den Brand, Stefan Dirnhofer, Gorana Gasljevic, Camille Laurent, Maurilio Ponzoni, Leticia Quintanilla-Martinez, Birgitta Sander and 1 more

Abstract readReview
In one paragraph

Review in Virchows Archiv : an international journal of pathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ioannis AnagnostopoulosInstitut für Pathologie, Julius-Maximilians Universität, Josef-Schneider-Straße 2, 97080, Würzburg, Germany. ioannis.anagnostopoulos@uni-wuerzburg.de.ORCID http://orcid.org/0000-0002-5043-6043
Tanja LakicFaculty of Medicine Novi Sad, University of Novi Sad and University Clinical Center of Vojvodina, Novi Sad, Serbia.ORCID http://orcid.org/0000-0003-4246-5132
Olga BalaguePathology Department, Hospital Clinic, Barcelona, Spain.ORCID http://orcid.org/0000-0002-5099-3675
Michiel Van den BrandDepartment of Pathology, Radboud University Medical Center, Nijmegen, the Netherlands.ORCID http://orcid.org/0000-0001-8871-6254
Stefan DirnhoferInstitute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, Basel, Switzerland.ORCID http://orcid.org/0009-0008-5250-3159
Gorana GasljevicDepartment of Pathology, Institute of Oncology, Ljubljana, Slovenia.ORCID http://orcid.org/0000-0002-8332-3627
Camille LaurentDepartment of Pathology, Cancer Institute, Toulouse University Hospital Center, University of Toulouse-Oncopole, Toulouse, France.ORCID http://orcid.org/0000-0002-5375-7512
Maurilio PonzoniAteneo Vita-Salute San Raffaele University, Hematopathology Diagnostic Area, San Raffaele Scientific Institute, Pathology Unit, Milan, Italy.ORCID http://orcid.org/0000-0002-0055-325X
Leticia Quintanilla-MartinezInstitut für Pathologie und Neuropathologie, Eberhard-Karls-Universität Tübingen and Comprehensive Cancer Center, University Hospital Tübingen, Tübingen, Germany.ORCID http://orcid.org/0000-0001-7156-5365
Birgitta SanderDepartment of Laboratory Medicine, Division of Pathology, Karolinska Institute and Karolinska University Hospital, Stockholm, Sweden.ORCID http://orcid.org/0000-0002-1214-1340
James R CookDepartment of Laboratory Medicine, Cleveland Clinic, Cleveland, OH, USA.ORCID http://orcid.org/0000-0003-0456-8085

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The challenging boundaries between neoplastic and reactive lymphoproliferations were discussed during the 2024 European Association for Haematopathology/Society for Hematopathology workshop in Dubrovnik, Croatia. Session 3 focussed on the atypical lymphoid proliferations associated with therapeutic interventions. Forty-four cases were submitted representing a broad spectrum of lymphoproliferative disorders (LPDs) encountered in the settings of immunosuppressive and immunomodulatory therapies, various interventions for solid tumor treatment, drug reaction with eosinophilia and systemic symptoms (DRESS), CAR T-cell therapy for B-cell lymphomas, Bruton tyrosine kinase inhibitors (BTKI) for SLL/CLL treatment, ABL-kinase inhibitor dasatinib, and COVID-19 vaccination. The cases of this session highlighted the importance of having sufficient clinical information including drug history and distribution of disease in order to achieve reliable diagnosis. Among LPDs associated with immunosuppressive and immunomodulatory therapies, the most challenging were T- and NK-derived infiltrates as they ranged from non-clonal to clonal. DRESS-associated lymphadenopathy exhibited variable histologic patterns with the most difficult differential diagnosis being with a T-cell lymphoma. LPDs observed after CAR T-cell therapy for B-cell neoplasms exhibited unexpected phenotypes resulting either from lineage switching/transdifferentiation, or from harvested T-cells already harbouring cancer-associated variants. Temporary interruption of BTKI treatment for CLL/SLL due to surgical procedures led to a "Pseudo-Richter transformation" that disappeared after reintroduction of therapy. Dasatinib led to a lymphadenopathy with a peculiar florid follicular hyperplasia that regressed after discontinuation of therapy. The findings of the few thoroughly studied COVID-19 vaccination associated lymphadenopathy cases reflected a disordered immune response. This report describes the most important features for diagnosis of these challenging cases.

Indexed as

Lymphoproliferative DisordersCOVID-19COVID-19 VaccinesHumansImmunosuppressive AgentsMiddle AgedCOVID-19 VaccinesImmunosuppressive AgentsCAR T-cell therapyCOVID-19 vaccinationDasatinib lymphadenopathyDRESSIatrogenic immunodeficiencyPseudo-Richter transformation

Identifiers

PMID40801926
PMCPMC12390900

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.